This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study
by Zacks Equity Research
Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.
Intuitive Surgical (ISRG) Q3 Earnings Match Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results reflect strong segmental performance.
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
Top Analyst Reports for Edwards Lifesciences, DexCom & Twitter
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences Corporation (EW), DexCom, Inc. (DXCM), and Twitter, Inc. (TWTR).
Quidel Corporation (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
Quidel's (QDEL) revenue growth in the third quarter is likely to have been boosted by robust sales of its SARS-related products.
Catalent (CTLT) Expands Presence in Japan Via New Facility
by Zacks Equity Research
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.
Here's Why You Should Add DexCom (DXCM) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool
by Zacks Equity Research
Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.
Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba
by Zacks Equity Research
Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.
Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
by Zacks Equity Research
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
If You Invested $1000 in DexCom 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
If You Invested $1000 in DexCom a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Stock Market News for Aug 2, 2021
by Zacks Equity Research
Benchmarks closed in the red on Friday, with renewed concerns revolving around the increase in coronavirus cases especially due to delta variant and a disappointing Q2 earnings report from Amazon.
DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.
DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 76.74% and 8.59%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for July 28th
by Zacks Equity Research
AEVA, BKD, CSGS, DXCM and EIG have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2021.
DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Analysts Estimate DexCom (DXCM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod
by Zacks Equity Research
Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.
New Strong Sell Stocks for July 13th
by Zacks Equity Research
ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021
New Strong Sell Stocks for July 6th
by Zacks Equity Research
DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021
Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus
by Debanjana Dey
CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.